Zymeworks Inc.
NASDAQ:ZYMEBiotechnology
-$0.38 today
- Market cap
- $1.80B
- Beta
- 1.14
- P/E (TTM)
- -16.6
- EPS (TTM)
- -$1.37
Volume 0.57M
Average 0.71M
ZYME Operating Expenses
Total costs of running the business that are not directly tied to producing goods or services sold.
Zymeworks Inc.NASDAQ: ZYME
Operating Expenses · Q3 FY2026 · quarter ended Sep 2026
Operating expenses growth accelerates
Q3 FY2026 operating expenses of $78.86M rose 58.6% year over year, ahead of the +5.9% change in trailing-twelve-month operating expenses. Sequentially, it rose 68.6% from the prior quarter. Over 3 fiscal years it compounded at -11.0% a year.
Context
- Operating expenses amounted to 187.3% of revenue in FY2025, down 92.4 pp from a year earlier.
- Operating expenses increased in 1 of the last 3 fiscal years.
What to watch
Whether quarterly growth of +58.6% holds above the trailing-twelve-month pace of +5.9%.
Sources:Income StatementText generated from reported figures; not investment advice.
Operating Expenses history
USD · from the income statement
- Latest · FY2025
- 198.5M USD
- Year-over-year change
- -7.0%
- 4-year CAGR
- -4.9%
| Period | Period end | Operating Expenses | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 198.5M | -7.0% |
| FY2024 | 2024-12-31 | 213.41M | +200.3% |
| FY2023 | 2023-12-31 | 71.08M | -74.8% |
| FY2022 | 2022-12-31 | 281.95M | +16.4% |
| FY2021 | 2021-12-31 | 242.31M | — |
Operating Expenses vs competitors
How ZYME compares with its peers on the latest reported figures
- ZYME's LTM Sep 2026 operating expenses of $217.29M is the 5th highest of the 11 companies compared; the peer median is $182.66M.
- Its year-over-year change of +5.9% is the 6th highest of 11, against a peer median of +6.0%.
- Operating expenses amounts to 81.7% of revenue for ZYME, versus a peer median of 244.8%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Sep 2026 | $333.75M | +278.1% | +101.5% | 297994.6% | |
| LTM Aug 2026 | $317.52M | +142.5% | +109.8% | 45.2% | |
| LTM Sep 2026 | $299.94M | +54.6% | +80.8% | — | |
| LTM Jun 2026 | $261.54M | +14.7% | +83.3% | 249.1% | |
| LTM Sep 2026 | $217.29M | +5.9% | -11.0% | 81.7% | |
| LTM Mar 2026 | $190.31M | -2.8% | -18.0% | 240.4% | |
| LTM Mar 2026 | $175.02M | +230.2% | +51.0% | 1472.9% | |
| LTM Mar 2026 | $173.51M | -10.6% | -12.1% | 110.5% | |
| LTM Mar 2026 | $99.95M | -10.4% | -13.9% | 281.2% | |
| LTM Mar 2026 | $91.02M | -33.2% | -6.5% | — | |
| LTM Mar 2026 | $33.28M | -2.6% | -8.4% | 45.8% | |
| Peer median (excluding ZYME) | $182.66M | +6.0% | +22.2% | 244.8% | |
Competitors are the stored peer set for ZYME. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Revenue | 26.68M | 412.48M | 76.01M | 76.3M | 105.97M |
| Cost of Revenue | 0 | 0 | 142.99M | 0 | 0 |
| Gross Profit | 26.68M | 412.48M | (66.98M) | 76.3M | 105.97M |
| Gross Margin | 100.0% | 100.0% | -88.1% | 100.0% | 100.0% |
| Research & Development | 199.75M | 208.6M | 143.62M | 134.62M | 137M |
| Selling, General & Admin | 42.6M | 73.4M | 70.4M | 61.5M | 61.5M |
| Operating Expenses | 242.31M | 281.95M | 71.08M | 213.41M | 198.5M |
| Depreciation & Amortization | 9.58M | 12M | 17.31M | 11.19M | 11.11M |
| EBITDA | (206.09M) | 142.49M | (120.7M) | (108.62M) | (68.64M) |
| EBITDA Margin | -772.4% | 34.5% | -158.8% | -142.4% | -64.8% |
| Operating Income | (215.63M) | 130.53M | (138.05M) | (137.11M) | (92.54M) |
| Operating Margin | -808.2% | 31.6% | -181.6% | -179.7% | -87.3% |
| Interest Income | 1.97M | 3.6M | 19.71M | 19.94M | 13.35M |
| Interest Expense | 0 | 0 | 0 | 0 | 0 |
| Other Income / Expenses | 3.27M | 4.71M | 18.81M | 20.5M | 12.78M |
| Income Before Tax | (212.36M) | 135.23M | (119.24M) | (116.61M) | (79.75M) |
| Pre-Tax Margin | -795.9% | 32.8% | -156.9% | -152.8% | -75.3% |
| Income Tax Expense | (516K) | 10.89M | (568K) | 6.08M | 1.38M |
| Net Income | (211.84M) | 124.34M | (118.67M) | (122.7M) | (81.13M) |
| Net Margin | -794.0% | 30.1% | -156.1% | -160.8% | -76.6% |
| EPS (Basic) | (4.06) | 1.91 | (1.72) | (1.62) | (1.08) |
| EPS (Diluted) | (4.61) | 1.90 | (1.72) | (1.62) | (1.08) |
| Weighted Avg Shares | 52.13M | 65.19M | 68.86M | 75.85M | 75.34M |
| Weighted Avg Shares (Diluted) | 52.13M | 65.25M | 68.86M | 75.88M | 75.34M |
Zymeworks Inc.
NASDAQ:ZYME
Intrinsic Alpha fair value
Locked
Current Price
$25.84
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.